Bilcare

Pune, India Founded: 1993 • Age: 33 yrs Listed Acquired By Lindsay Goldberg
Pharmaceutical packaging, clinical supplies, and anti-counterfeiting solutions are provided.
Request Access
Report Incorrect Data
Page last updated

About Bilcare

Bilcare is a publicly listed company based in Pune (India) founded in 1993 by Mohan Bhandari, and was acquired by Lindsay Goldberg in September 2019. Pharmaceutical packaging, clinical supplies, and anti-counterfeiting solutions are provided. The company has 78 employees. Bilcare has completed 1 acquisition, including Singular ID. Its chief executive, as recorded, is Mohan Bhandari. Its website bilcare.com draws about 10 thousand monthly visits. Its Indian entity Bilcare Limited reported revenue of ₹764 Cr. Bilcare offers products and services including Blister Films, Blister Foils, Lidding Foils, Aluminum Foils, and Polymer Films. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation. Its competitors include Akums, Jubilant Life Sciences and Nectar Lifesciences; 2 of its 3 listed competitors have raised funding.

Company details

Bilcare is a pharma packaging solutions provider. The company has 3 major divisions - Pharmaceutical Packaging International (PPI), Global Clinical Material Supplies (GCS) and non-clonable ID technologies. The PPI division offers packaging solutions mainly for solid dose packaging through specialty Polymer Films and Aluminum Foils. The GCS division offers clinical trial supply management services such as clinical supplies packaging and labelling, controlled-temperature (cold chain) CTM storage, worldwide distribution and returns and destructions accountability etc. The non-clonable ID technologies division offers track and trace, authentication and Anti-counterfeit (trademarked nCID technology - nonclonableID) solutions for product; people ID authentication and security. The company has 9 manufacturing facilities spread across Europe, US and Asia. Bilcares clientele includes Bristol-Myers Squibb, Dr. Reddys, GlaxoSmithKline, Johnson Johnson, Merck, Novartis, Pfizer, Ranbaxy, Sanofi-Aventis, and Teva, among others.

  • Headquarters Pune, India
  • Employees 78
  • Founders Mohan Bhandari
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website bilcare.com
  • Social LinkedIn X Facebook YouTube
  • Acquired by Lindsay Goldberg (Sep 2019)
  • Legal Name Bilcare Ltd
Operational Areas
Healthcare → Biopharma Outsourcing & Drug Delivery
Key Metrics
  • Market Cap
    ₹201 Cr

    BI · NSE

  • Share Price
    ₹83.85

    -2.00% today

  • Revenue
    ₹734 Cr

    FY 2025-26 · -6.9% YoY

  • EBITDA
    ₹40.63 Cr

    Margin 5.5%

  • Net Profit
    ₹5.52 Cr

    FY 2025-26 · +121.9% YoY

  • P/E (TTM)
    10.2x

    P/B 1.0x

  • Latest Funding Round
    $116.1M (USD), Debt – Conventional

    Aug 2014

  • Investors
    ISM Capital

    & 2 more

  • Employee Count
    78
  • Investments & Acquisitions
    Singular ID

  • Acquired by
    Lindsay Goldberg

    (Sep 2019)

Products & Services of Bilcare

Bilcare offers a comprehensive portfolio of products and services, including Blister Films, Blister Foils, Lidding Foils, Aluminum Foils, and Polymer Films.

Blister Films
Packaging Material

Materials for pharmaceutical blister packaging protection.

Blister Foils
Packaging Material

Foils used in drug packaging for barrier properties.

Lidding Foils
Packaging Material

Sealing foils for pharmaceutical containers.

Aluminum Foils
Packaging Material

Foils providing protection against counterfeiting.

Polymer Films
Packaging Material

Films for innovative and sustainable packaging solutions.

Apps and channels of Bilcare

its YouTube channel Bilcare Ltd has 155 subscribers and 18 videos.

Bilcare Ltd
YouTube 155 subscribers 18 videos Science & Technology
Open channel

Videos from Bilcare

The most watched videos on Bilcare's YouTube channel, Bilcare Ltd (155 subscribers). Click a video to play it here.

BILCARE Corporate Film
3K views
Bilcare corporate film
487 views
BilcareOptima
486 views
Bilcare 2015
473 views

More on Bilcare Ltd.

Funding Insights of Bilcare

  • Total Rounds 2
  • Last Round Debt – Conventional — $116.1M
  • First Round $33.3M

    (Feb 2010)

  • Investors Count 2

All 2 funding rounds of Bilcare with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Aug 2014$116.1MDebt – Conventional––
Proventus
Feb 2010$33.3MPost-IPO––
ISM Capital
Valuation history

3 investors in total: 3 institutional.

Investors in Bilcare

Bilcare has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include ISM Capital, Proventus and Lindsay Goldberg.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Proventus
A family office is operated across Nordic and European regions.
proventus.seStockholm, Sweden
Lindsay Goldberg
PE firm invests in the US
lindsaygoldbergllc.comNew York, United States
ISM Capital
Financial solutions are provided for the investment industry.
2008ismcapital.comLondon, United Kingdom
Premium access

Investor details for Bilcare

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Bilcare Limited (Bilcare)

Bilcare Limited is the primary company behind Bilcare. The board of Bilcare Limited currently have 8 directors; the longest-serving is Mohan Harakchand Bhandari, appointed in 1987. 35 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Mohan Harakchand Bhandari
DIN 00052777
CEO01 Jul 198739 yrs 3 moBilcare Limited
Rajesh Shankarrao Devene
DIN 05320201
Director22 Apr 20197 yrs 6 moBilcare Limited
Shreyans Mohan Bhandari
DIN 07737337
Managing Director01 Jul 20224 yrs 3 moBilcare Limited
Kavita Bhansali
DIN 05355200
Whole-time director14 Aug 20233 yrs 2 moBilcare Limited
Deepa Mathur
DIN 00449912
CFO07 Oct 20233 yrsBilcare Limited
Sagar Ramnarayan Baheti
DIN 08402716
Company Secretary08 Feb 20242 yrs 8 moBilcare Limited
Alka Sagar
DIN 07138477
Director14 Aug 20242 yrs 2 moBilcare Limited
Ashwini Ashok Hasabnis
DIN 07766525
Additional Director25 Apr 20266 moBilcare Limited

People of Bilcare

37 people are tracked at Bilcare (9 in leadership, 5 in board & advisors, 23 in team); the tracked headcount is 78.

NameRoleGroup
Mohan Bhandari
Founder & CEOLeadership
Mohan H. Bhandari
Executive Director, Chairman & MDLeadership
Gopal Paradiya
General ManagerLeadership
Debadutta Mishra
Vice President - Global Strategic Business Development | Business Head - PPI (singapore)Leadership
V.s. Ananth
Regional Business Head - SouthLeadership
Cr Raghu
Head S H ELeadership
Shyam Singh
Vice President OperationsLeadership
Chhanda Das
VP Quality And RegulatoryLeadership
Rajneesh Kumar
Head- Costing & MISLeadership
Vijesh Mehra
Non-Executive, Independent DirectorBoard & advisors
Rajesh S. Devene
DirectorBoard & advisors
Madhuri Vaidya
DirectorBoard & advisors
Diksha Tomar
Non-Executive, Independent DirectorBoard & advisors
Ashwani Singh
DirectorBoard & advisors
Vitthal Chitte
Executive - SCM (purchase / Materials)Team
Ashwini Gore
Quality Assurance And Quality ControlTeam
Pravin Desai
Technical Quality ManagerTeam
Sandeep Shirwadkar
Sr.accounts ExecutiveTeam
Pravin Jagtap
Manager QA & RATeam
Laxmikant Nawale
Assistant ManagerTeam

17 more people are available in the full profile.

Premium access

Complete people profiles for Bilcare

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Bilcare

Bilcare is a publicly listed company on the BSE with ticker symbol BI in India, operating in the Process industries sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date25 Apr 1995
  • Listed onBSE: 526853
  • Listed entityBilcare Ltd
  • Exchange sectorProcess industries
  • ISININE986A01012
  • Share price₹69.99 (-2.82% on the day) · 2026-05-11
  • Market capitalisation₹170 Cr
  • Price to earnings29.8
  • EPS (diluted, trailing year)₹-4.88
  • Volume (last session)5,213
  • Analyst consensusNo rating

Financials of Bilcare

Exchange-reported figures of Bilcare Limited, the listed company behind Bilcare (NSE: BI).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹734 Cr
-6.9% YoY
EBITDA
₹40.63 Cr
+63.9% YoY
Profit After Tax
₹5.52 Cr
+121.9% YoY
Net Worth
₹197 Cr
-8.2% YoY
Total Assets
₹708 Cr
-11.1% YoY
Total Debt
₹620 Cr
-10.0% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue7347887479828456231,827
Revenue growth-6.9%+5.5%-23.9%+16.2%+35.7%-65.9%-
EBITDA40.6324.7932.51(26.13)56.8646.3643.99
EBITDA margin+5.5%+3.2%+4.4%-2.7%+6.7%+7.4%+2.4%
Profit before tax(21.46)(71.34)(71.71)196(4.22)(24.96)(114)
Net profit5.52(25.26)(32.14)(66.54)(42.65)(42.56)(299)
Net profit margin+0.8%-3.2%-4.3%-6.8%-5.1%-6.8%-16.4%
EPS (₹)0.73(12.23)(14.12)6.39(5.35)(8.95)(43.97)
Balance sheet
Total assets7087961,4061,346877898948
Net worth19721449853175.1586.31108
Total debt620689756639690677707
Cash & bank5.5115.0136.4230.8340.0756.6464.13
Net working capital222222272128171171202
Cash flow
Cash from operations12886.4162.46(6.98)41.2771.79256
Cash from investing(5.02)81.41(106)36.20(4.26)1.651,309
Cash from financing(132)(171)35.89(18.90)(54.88)(82.68)(1,600)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue226188181178186194198202
Revenue growth (YoY)+21.2%-3.3%-8.5%-11.7%-4.0%---
Other income1.7514.465.144.326.0821.163.443.91
EBITDA35.2814.9311.213.4211.077.680.75(2.28)
EBITDA margin+15.6%+8.0%+6.2%+1.9%+5.9%+4.0%+0.4%-1.1%
Depreciation4.114.785.0112.2311.564.6611.7411.04
Interest18.0817.6917.0419.0618.5518.6819.4823.68
Profit before tax14.846.92(5.70)(23.55)(12.96)5.50(27.03)(33.09)
Tax(0.13)(0.93)0.19(0.23)(3.20)(6.56)(10.79)(3.16)
Net profit14.977.85(5.89)(23.32)(9.76)12.06(16.24)(29.93)
EPS (₹)5.395.680.41(5.25)(1.61)7.47(3.05)(6.81)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue6.8515.1217.6013.98430304212
Revenue growth-54.7%-14.1%+25.9%-96.8%+41.3%+43.6%-
EBITDA(14.65)(5.67)(13.31)(87.82)31.2820.55(247)
EBITDA margin-213.9%-37.5%-75.6%-628.2%+7.3%+6.8%-116.7%
Profit before tax1.565.465.69503(23.53)(17.63)(127)
Net profit2.582.14(10.80)(8.82)(51.33)(52.79)(126)
Net profit margin+37.7%+14.2%-61.4%-63.1%-11.9%-17.4%-59.7%
EPS (₹)0.421.702.27165.97(7.55)0.76(43.46)
Balance sheet
Total assets433434426418757793831
Net worth42142041641043.4160.7259.18
Total debt11.8711.0410.297.52690678709
Cash & bank1.303.492.0511.984.527.815.44
Net working capital49.4567.1156.96(12.56)(0.70)7.66(51.61)
Cash flow
Cash from operations11.572.3697.6339746.29(0.41)71.12
Cash from investing(14.05)2.94(107)1815.5985.0210.82
Cash from financing0.24(3.85)(0.51)(571)(55.47)(82.28)(83.03)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1.941.201.731.852.074.133.362.76
Revenue growth (YoY)-6.3%-70.9%-48.5%-33.0%-57.5%---
Other income4.363.825.543.456.726.453.783.78
Total expenses4.6711.263.553.213.485.703.885.49
EBITDA(2.73)(10.06)(1.82)(1.36)(1.41)(1.57)(0.52)(2.73)
EBITDA margin-140.7%-838.3%-105.2%-73.5%-68.1%-38.0%-15.5%-98.9%
Depreciation0.600.610.710.720.680.600.770.77
Interest0.120.140.150.170.140.060.123.04
Profit before tax0.91(6.99)2.861.204.494.222.37(2.76)
Tax(0.13)(0.64)0.150.160.900.860.56(0.19)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 24 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue226188181178186194198202
Revenue growth (YoY)+21.2%-3.3%-8.5%-11.7%-4.0%---
Other income1.7514.465.144.326.0821.163.443.91
EBITDA35.2814.9311.213.4211.077.680.75(2.28)
EBITDA margin+15.6%+8.0%+6.2%+1.9%+5.9%+4.0%+0.4%-1.1%
Depreciation4.114.785.0112.2311.564.6611.7411.04
Interest18.0817.6917.0419.0618.5518.6819.4823.68
Profit before tax14.846.92(5.70)(23.55)(12.96)5.50(27.03)(33.09)
Tax(0.13)(0.93)0.19(0.23)(3.20)(6.56)(10.79)(3.16)
Net profit14.977.85(5.89)(23.32)(9.76)12.06(16.24)(29.93)
EPS (₹)5.395.680.41(5.25)(1.61)7.47(3.05)(6.81)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue7347887479828456231,827
Revenue growth-6.9%+5.5%-23.9%+16.2%+35.7%-65.9%-
Other income30.0032.2522.5232047.1049.78255
Total expenses6937637151,0087885761,783
Employee cost0.0081.0771.8771.2659.2755.30371
EBITDA40.6324.7932.51(26.13)56.8646.3643.99
EBITDA margin+5.5%+3.2%+4.4%-2.7%+6.7%+7.4%+2.4%
Depreciation19.7545.8844.9537.8139.2545.51239
Interest72.3482.5081.7960.0068.9375.59174
Profit before tax(21.46)(71.34)(71.71)196(4.22)(24.96)(114)
Tax(4.17)(15.18)(13.17)1460.14(13.79)(14.62)
Net profit5.52(25.26)(32.14)(66.54)(42.65)(42.56)(299)
Net profit margin+0.8%-3.2%-4.3%-6.8%-5.1%-6.8%-16.4%
EPS (₹)0.73(12.23)(14.12)6.39(5.35)(8.95)(43.97)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital23.5523.5523.5523.5523.5523.5523.55
Reserves & surplus17319147450751.6062.7684.74
Shareholders' funds (net worth)19721449853175.1586.31108
Minority interest(123)(125)14817386.1777.8967.88
Secured loans595569666518445438471
Unsecured loans25.6412090.42120245239236
Total debt620689756639690677707
Total liabilities7087961,4061,346877898948
Assets
Gross block9139262,0732,0871,0031,0651,746
Net block4324561,0381,045465494534
Capital work in progress9.603.831.280.730.700.500.32
Investments14.2010.707.662.460.010.010.22
Inventories11511710684.0913610176.97
Sundry debtors108119150188220154108
Cash & bank balances5.5115.0136.4230.8340.0756.6464.13
Loans & advances12591.9811940.5724.1225.53116
Total current assets353343411343421337365
Total current liabilities132121139216250166163
Net working capital222222272128171171202
Total assets7087961,4061,346877898948
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash14.1417.0024.4714.1632.0341.2775.88
Net cash from operating activities12886.4162.46(6.98)41.2771.79256
Net cash from investing activities(5.02)81.41(106)36.20(4.26)1.651,309
Net cash from financing activities(132)(171)35.89(18.90)(54.88)(82.68)(1,600)
Net change in cash(9.53)(2.86)(7.47)10.31(17.87)(9.24)(34.61)
Closing cash5.5115.0136.4230.8340.0756.6464.13
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-6.9%+5.5%-23.9%+16.2%+35.7%-65.9%-
EBITDA growth+63.9%-23.8%+224.4%-146.0%+22.7%+5.4%-
PBT growth+69.9%+0.5%-+9998.0%+83.1%+78.0%+73.7%
Net income growth+121.9%+21.4%+51.7%-56.0%-0.2%+85.8%-
Revenue CAGR (3Y)-9.3%-2.3%+6.3%-18.7%-34.4%-39.3%-11.5%
EBITDA CAGR (3Y)--24.2%-11.2%--30.4%-33.5%-38.4%
Profitability & leverage
Net income margin-2.4%-7.1%-7.8%+5.1%-0.5%-1.8%-5.4%
Return on capital employed--0.0%+2.8%0.0%0.0%0.0%
Return on net worth--0.0%-8.3%0.0%0.0%0.0%
Debt / equity--1.984.728.477.1177.39
Long-term debt / equity--1.513.746.615.5933.91
Interest cover346.46-391.18-657.48-93.84391.438,892.94-89.40
Efficiency & per share
Fixed asset turnover--0.390.710.820.440.58
Inventory turnover--7.858.907.127.008.19
Debtors turnover--4.434.814.514.758.76
EPS (₹)0.73(12.23)(14.12)6.39(5.35)(8.95)(43.97)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.00199.21211.4487.6531.9136.6645.99
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1.941.201.731.852.074.133.362.76
Revenue growth (YoY)-6.3%-70.9%-48.5%-33.0%-57.5%---
Other income4.363.825.543.456.726.453.783.78
Total expenses4.6711.263.553.213.485.703.885.49
EBITDA(2.73)(10.06)(1.82)(1.36)(1.41)(1.57)(0.52)(2.73)
EBITDA margin-140.7%-838.3%-105.2%-73.5%-68.1%-38.0%-15.5%-98.9%
Depreciation0.600.610.710.720.680.600.770.77
Interest0.120.140.150.170.140.060.123.04
Profit before tax0.91(6.99)2.861.204.494.222.37(2.76)
Tax(0.13)(0.64)0.150.160.900.860.56(0.19)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue6.8515.1217.6013.98430304212
Revenue growth-54.7%-14.1%+25.9%-96.8%+41.3%+43.6%-
Other income19.5317.8523.6459648.0271.17278
Total expenses21.5020.7930.91102399284459
Employee cost0.005.425.975.7533.6732.0827.30
EBITDA(14.65)(5.67)(13.31)(87.82)31.2820.55(247)
EBITDA margin-213.9%-37.5%-75.6%-628.2%+7.3%+6.8%-116.7%
Depreciation2.722.872.154.5234.6434.6388.06
Interest0.603.852.490.4568.1974.7269.08
Profit before tax1.565.465.69503(23.53)(17.63)(127)
Tax0.571.460.36112(5.76)(19.39)(24.23)
Net profit2.582.14(10.80)(8.82)(51.33)(52.79)(126)
Net profit margin+37.7%+14.2%-61.4%-63.1%-11.9%-17.4%-59.7%
EPS (₹)0.421.702.27165.97(7.55)0.76(43.46)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital23.5523.5523.5523.5523.5523.5523.55
Reserves & surplus39739639238719.8637.1735.63
Shareholders' funds (net worth)42142041641043.4160.7259.18
Secured loans0.860.000.000.00445438471
Unsecured loans11.0111.0410.297.52245240238
Total debt11.8711.0410.297.52690678709
Total liabilities433434426418757793831
Assets
Gross block71.4476.4177.9554.979099011,586
Net block57.6260.8263.4116.25446473506
Capital work in progress0.000.000.000.000.000.080.00
Investments31029429429480.5189.49173
Inventories0.180.380.510.8256.2344.4222.22
Sundry debtors2.043.414.899.4592.6372.2839.10
Cash & bank balances1.303.492.0511.984.527.815.44
Loans & advances64.8676.0182.670.5015.8818.4823.59
Total current assets68.3883.2990.1222.7516914390.35
Total current liabilities18.9316.1833.1635.31170135142
Net working capital49.4567.1156.96(12.56)(0.70)7.66(51.61)
Total assets433434426418757793831
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash2.641.1911.133.667.254.926.00
Net cash from operating activities11.572.3697.6339746.29(0.41)71.12
Net cash from investing activities(14.05)2.94(107)1815.5985.0210.82
Net cash from financing activities0.24(3.85)(0.51)(571)(55.47)(82.28)(83.03)
Net change in cash(2.24)1.45(9.94)7.47(3.59)2.33(1.08)
Closing cash1.303.492.0511.984.527.815.44
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-54.7%-14.1%+25.9%-96.8%+41.3%+43.6%-
EBITDA growth-158.4%+57.4%+84.8%-380.8%+52.2%+108.3%-
PBT growth-71.4%-4.0%-98.9%+9998.0%-33.5%+86.1%+59.7%
Net income growth+20.6%+119.8%-22.5%+82.8%+2.8%+58.2%-
Revenue CAGR (3Y)-21.2%-67.2%-61.3%-59.6%+21.5%+5.7%-9.5%
EBITDA CAGR (3Y)-45.0%---29.2%--+342.6%
Profitability & leverage
Net income margin+14.5%+26.5%+30.3%+2795.4%-4.1%+0.6%-48.3%
Return on capital employed-+1.0%-1.3%-1.1%0.0%+0.2%0.0%
Return on net worth-+0.3%-1.7%-2.5%0.0%-14.8%0.0%
Debt / equity-0.030.021.5413.1411.577.14
Long-term debt / equity-0.020.021.2010.249.085.77
Interest cover-3.45-45.08-16.11-0.49-2,029.46-530.68-20.61
Efficiency & per share
Fixed asset turnover-0.200.260.030.470.240.13
Inventory turnover-33.9826.470.498.549.137.86
Debtors turnover-3.642.450.275.215.465.56
EPS (₹)0.421.702.27165.97(7.55)0.76(43.46)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.00178.24176.54174.3018.4425.7925.13

Investments & Acquisitions by Bilcare

Bilcare has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Singular ID.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Singular ID
Unique identification services are provided since 2004 in Singapore.
singular-id.comSingapore2004Dec 2007$13.53M
Premium access

Complete acquisition details for Bilcare

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Bilcare

6 dated milestones of Bilcare across 26 years, from founding to its latest funding, stage changes and deals.

  1. Founded Bilcare is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Acquisition Acquires Singular ID.
  4. Funding First funding round of $33.3M.
  5. Funding Latest funding round, Debt – Conventional, of $116.1M.
  6. Exit Acquired by Lindsay Goldberg.

Competitors of Bilcare

Bilcare has 3 listed competitors in our database, 2 of them funded. They include Akums, Jubilant Life Sciences and Nectar Lifesciences.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Akums
akums.in2004Delhi, India$70M395
CDMO focusing on spectrum of dosage forms and therapeutic segments
Jubilant Life Sciences
jubl.com1978Noida, India
Company offering a suite of R&D and manufacturing services for small molecules and generics
Nectar Lifesciences
neclife.com1995Chandigarh, India$46.85M175
Cephalosporin APIs and generic formulations are manufactured.
Premium access

Detailed competitors of Bilcare

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Bilcare

The website of Bilcare (bilcare.com) receives about 10.4K visits a month.

  • Monthly visits
    10.4K

    ▲ 228.1% vs previous month

Similar websites

Websites whose visitors overlap most with Bilcare. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
hotfrog.in
hotfrog.in
100%
#586,439–
Hoover's
hoovers.com
87%
2.7K#7,400,191View details
Tata Consultancy Services
tcs.com
86%
2.6M#27,194View details
minocherpatel.com
minocherpatel.com
84%
#12,245,955–
bilcareacademy.com
bilcareacademy.com
48%
–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 6 similar websites and full traffic analytics for Bilcare

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 6 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Bilcare (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Anthem Biosciences
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M1,820
Laurus Labs
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M12,470
Entero Healthcare
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M4,260
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Bilcare

Galaxy Surfactants Ltd leads gainers in 'B' group | Capital Market News - Business Standard
Business Standard • 2 months ago
Bilcare Approves Subscription To Warrants Worth 960 Mln Rupees Issued By Unit Caprihans India
Reuters • 1 year ago
Bilcare Q1 Results Live: loss falls by 19.22% YOY
Livemint • 2 years ago
Bilcare June-Quarter Consol Net Loss 63.9 Million Rupees
Reuters • 2 years ago
Bilcare Says Names Deepa Mathur As CFO
Reuters • 3 years ago
Bilcare Says Nilesh Tiwari Resigns As CFO
Reuters • 3 years ago
Bilcare Says Initiation Of Corporate Insolvency Process Stayed By Appellate Tribunal
Reuters • 3 years ago
Bilcare Sept-Quarter Consol Net Profit 224 Million Rupees
Reuters • 4 years ago
Bilcare Standalone June 2021 Net Sales at Rs 86.94 crore, up 19.51% Y-o-Y
Moneycontrol • 5 years ago
Bilcare June Qtr Consol Net Loss Narrows
Reuters • 5 years ago
Premium access

Complete news archive for Bilcare

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Bilcare

Bilcare was founded in 1993 and raised its 1st funding round 17 years after it was founded.

Bilcare is headquartered in Pune, India. It is registered at Pune, Maharashtra, India.

Mohan Bhandari is the CEO of Bilcare, as recorded in our data. They have also founded this company.

Bilcare has 78 employees.

The primary company behind Bilcare, Bilcare Limited, reported revenue of ₹764 Cr for FY 2026, down 7% year on year.

Bilcare is a pharma packaging solutions provider. The company has 3 major divisions - Pharmaceutical Packaging International (PPI), Global Clinical Material Supplies (GCS) and non-clonable ID technologies. The PPI division offers packaging solutions mainly for solid dose packaging through specialty Polymer Films and Aluminum Foils. The GCS division offers clinical trial supply management services such as clinical supplies packaging and labelling, controlled-temperature (cold chain) CTM storage, worldwide distribution and returns and destructions accountability etc. The non-clonable ID technologies division offers track and trace, authentication and Anti-counterfeit (trademarked nCID technology - nonclonableID) solutions for product; people ID authentication and security. The company has 9 manufacturing facilities spread across Europe, US and Asia. Bilcares clientele includes Bristol-Myers Squibb, Dr. Reddys, GlaxoSmithKline, Johnson Johnson, Merck, Novartis, Pfizer, Ranbaxy, Sanofi-Aventis, and Teva, among others.

Bilcare's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.

Bilcare offers Blister Films, Blister Foils, Lidding Foils, Aluminum Foils, and Polymer Films.

Yes, Bilcare is publicly traded on BSE under the ticker symbol BI.

Bilcare has made 1 acquisition, including Singular ID.

Bilcare has 3 investors. Key investors include ISM Capital, Proventus, and Lindsay Goldberg.

Bilcare operates through Bilcare Limited.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available